Currently, a reliable method for identifying breast cancer patients likely to fail therapy and suffer recurrence of the disease does not exist. A prognostic tool that would enable doctors to consider alternate treatments for patients likely to fail standard regimens would be valuable. BIOwulf funded a study based on a sample of 73 patients from which 49 patients had seen no recurrence. The study used 20 variables from preprocessed clinical data such as: progesterone receptors, age, positive lymph nodes and total nodes surgically removed to determine what variables were critical for prediction. Based on clinical data alone, a "diagnostic pattern" was revealed that was able to accurately identify three out of four women who ultimately failed chemotherapy treatment. BIOwulf and its team of scientists expect to improve upon these results through incorporation of genomic and/or proteomic data from the tissues associated with these cases.